The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are now reviewing the ... The announcement marks a potential advancement for SMA care and has been positively ...
Solana price faces another 30% decline if the altcoin is unable to defend $110 level during further market corrections.
Now, the CHMP has backed conditional approval of Zolgensma for babies and young children with SMA, which could lead to full EMA approval within the next couple of months. Novartis says it will ...
Evrysdi is designed to treat SMA by increasing and sustaining the production ... Evrysdi was granted PRIME designation by the European Medicines Agency (EMA) in 2018 and Orphan Drug Designation ...